This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bridges, C. R. Search for Related Content PubMed PubMed Citation Articles by Bridges, C. R. Related Collections Cardiovascular Pharmacology CV surgery: other

(Circulation. 2007;115:2790-2792.)
© 2007 American Heart Association, Inc.

Editorial

Valid Comparisons of Antifibrinolytic Agents Used in Cardiac Surgery

Charles R. Bridges, MD, ScD

From the Division of Cardiothoracic Surgery, University of Pennsylvania Medical Center, Philadelphia.

Correspondence to Charles R. Bridges, MD, ScD, Division of Cardiothoracic Surgery, University of Pennsylvania Medical Center, 230 W Washington Sq, 3rd Floor, Philadelphia, PA 19106. E-mail Charles.Bridges@uphs.upenn.edu

Key Words: Editorials • antifibrinolytic agents • surgery • complications

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Bleeding is a major source of morbidity and mortality after cardiac surgical procedures. Patients who return to the operating room for bleeding have a 4-fold increase in mortality and a similar increase in the rate of sternal infection. The significance of this issue is underscored by the fact that patients undergoing cardiac surgery consume up to 30% of the nation’s blood supply. During massive hemorrhage resulting from trauma, the life-saving benefits of blood transfusion are well documented. However, in the more common setting of elective blood and blood component transfusions in intensive care units using arbitrary transfusion triggers, the benefits of transfusion are not well established and may have a net negative influence on outcomes. Indeed, the overt dangers of transfusion are unequivocal (hepatitis C, HIV, fever, infection, increased costs, transfusion reaction), and evidence of the covert dangers of blood transfusion (prolonged intensive care unit stay, increased mortality, increased morbidity) after cardiac surgery is persuasive.¹ Because both bleeding itself and the transfusions administered to compensate for blood loss have an untoward impact on outcomes, there is strong motivation to decrease the occurrence of bleeding associated with cardiac surgical procedures in the first place. In this regard, the Society of Thoracic Surgeons Workforce on Evidence Based Surgery, in conjunction with the Society of Cardiovascular Anesthesiologists, recently published a comprehensive guideline outlining appropriate methods for blood conservation in cardiac surgery.²

Article p 2801

Recently, Mangano et al published the short-term³ and longer-term⁴ results of the same observational study comparing the 3 antifibrinolytic . . . [Full Text of this Article]

This article has been cited by other articles:

				P. E. Greilich, M. E. Jessen, N. Satyanarayana, C. W. Whitten, G. A. Nuttall, J. M. Beckham, M. H. Wall, and J. F. Butterworth The Effect of Epsilon-Aminocaproic Acid and Aprotinin on Fibrinolysis and Blood Loss in Patients Undergoing Primary, Isolated Coronary Artery Bypass Surgery: A Randomized, Double-Blind, Placebo-Controlled, Noninferiority Trial Anesth. Analg., July 1, 2009; 109(1): 15 - 24. [Abstract] [Full Text] [PDF]